These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38229349)

  • 41. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort.
    Petri M; Purvey S; Fang H; Magder LS
    Arthritis Rheum; 2012 Dec; 64(12):4021-8. PubMed ID: 22932985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.
    Bruce IN; O'Keeffe AG; Farewell V; Hanly JG; Manzi S; Su L; Gladman DD; Bae SC; Sanchez-Guerrero J; Romero-Diaz J; Gordon C; Wallace DJ; Clarke AE; Bernatsky S; Ginzler EM; Isenberg DA; Rahman A; Merrill JT; Alarcón GS; Fessler BJ; Fortin PR; Petri M; Steinsson K; Dooley MA; Khamashta MA; Ramsey-Goldman R; Zoma AA; Sturfelt GK; Nived O; Aranow C; Mackay M; Ramos-Casals M; van Vollenhoven RF; Kalunian KC; Ruiz-Irastorza G; Lim S; Kamen DL; Peschken CA; Inanc M; Urowitz MB
    Ann Rheum Dis; 2015 Sep; 74(9):1706-13. PubMed ID: 24834926
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus.
    Samões B; Zen M; Abelha-Aleixo J; Gatto M; Doria A
    Autoimmun Rev; 2022 Oct; 21(10):103165. PubMed ID: 35931316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low disease activity state in juvenile-onset systemic lupus erythematosus.
    Ozturk K; Caglayan S; Tanatar A; Baglan E; Yener Otar G; Kavrul Kayaalp G; Karadag SG; Demir F; Sonmez HE; Ozdel S; Cakan M; Aktay Ayaz N; Sozeri B;
    Lupus; 2021 Nov; 30(13):2144-2150. PubMed ID: 34723709
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicting lupus low disease activity state and remission in SLE: novel insights.
    Gao D; Hao Y; Fan Y; Ji L; Zhang Z
    Expert Rev Clin Immunol; 2021 Oct; 17(10):1083-1089. PubMed ID: 34392757
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study.
    Louthrenoo W; Kasitanon N; Morand E; Kandane-Rathnayake R
    Arthritis Res Ther; 2020 Jan; 22(1):8. PubMed ID: 31924267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus.
    Gao D; Hao Y; Mu L; Xie W; Fan Y; Ji L; Zhang Z
    Rheumatology (Oxford); 2020 Nov; 59(11):3400-3407. PubMed ID: 32337549
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The SLICC-FI Predicts Damage Accrual in SLE Patients. Data From the Almenara Lupus Cohort.
    Elera-Fitzcarrald C; Gamboa-Cárdenas RV; Reatégui-Sokolova C; Pimentel-Quiroz V; Rodriguez-Bellido Z; Pastor-Asurza CA; Perich-Campos R; Alarcón GS; Ugarte-Gil MF
    Lupus; 2022 Nov; 31(13):1666-1670. PubMed ID: 36165429
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index.
    Legge A; Kirkland S; Rockwood K; Andreou P; Bae SC; Gordon C; Romero-Diaz J; Sanchez-Guerrero J; Wallace DJ; Bernatsky S; Clarke AE; Merrill JT; Ginzler EM; Fortin PR; Gladman DD; Urowitz MB; Bruce IN; Isenberg DA; Rahman A; Alarcón GS; Petri M; Khamashta MA; Dooley MA; Ramsey-Goldman R; Manzi S; Zoma AA; Aranow C; Mackay M; Ruiz-Irastorza G; Lim SS; Inanc M; van Vollenhoven RF; Jonsen A; Nived O; Ramos-Casals M; Kamen DL; Kalunian KC; Jacobsen S; Peschken CA; Askanase A; Hanly JG
    Arthritis Rheumatol; 2020 Apr; 72(4):658-666. PubMed ID: 31631584
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Damage accrual in southern Chinese patients with systemic lupus erythematosus.
    Mok CC; Ho CT; Wong RW; Lau CS
    J Rheumatol; 2003 Jul; 30(7):1513-9. PubMed ID: 12858450
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus.
    Emamikia S; Oon S; Gomez A; Lindblom J; Borg A; Enman Y; Morand E; Grannas D; van Vollenhoven RF; Nikpour M; Parodis I
    Rheumatology (Oxford); 2022 Nov; 61(12):4752-4762. PubMed ID: 35302581
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Which extra-renal flare is 'difficult to treat' in systemic lupus erythematosus? A one-year longitudinal study comparing traditional and machine learning approaches.
    Maffi M; Tani C; Cascarano G; Scagnellato L; Elefante E; Stagnaro C; Carli L; Ferro F; Signorini V; Zucchi D; Cardelli C; Trentin F; Collesei A; Mosca M
    Rheumatology (Oxford); 2024 Feb; 63(2):376-384. PubMed ID: 37094218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disease course following High Disease Activity Status revealed patterns in SLE.
    Hoi A; Koelmeyer R; Bonin J; Sun Y; Kao A; Gunther O; Nim HT; Morand E
    Arthritis Res Ther; 2021 Jul; 23(1):191. PubMed ID: 34261522
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study.
    Morand EF; Isenberg DA; Wallace DJ; Kao AH; Vazquez-Mateo C; Chang P; Pudota K; Aranow C; Merrill JT
    Rheumatology (Oxford); 2020 Oct; 59(10):2930-2938. PubMed ID: 32107560
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort.
    Quintana R; Pons-Estel GJ; Roberts K; Sacnún M; Serrano R; Nieto R; Conti S; Gervasoni V; Catoggio LJ; Soriano ER; Scolnik M; García MA; Alvarellos A; Saurit V; Berbotto GA; Sato EI; Costallat LTL; Neto EFB; Bonfa E; Xavier RM; de Oliveira E Silva Montandon AC; Molina-Restrepo JF; Iglesias-Gamarra A; Guibert-Toledano M; Reyes-Llerena GA; Massardo L; Neira OJ; Cardiel MH; Barile-Fabris LA; Amigo MC; Silveira LH; Torre IG; Acevedo-Vásquez EM; Ugarte-Gil MF; Alfaro-Lozano JL; Segami MI; Chacón-Díaz R; Esteva-Spinetti MH; Gomez-Puerta JA; Alarcón GS; Pons-Estel BA
    Lupus; 2020 Aug; 29(9):1140-1145. PubMed ID: 32605527
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.
    Oon S; Huq M; Golder V; Ong PX; Morand EF; Nikpour M
    Ann Rheum Dis; 2019 May; 78(5):629-633. PubMed ID: 30679152
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study.
    Yavuz S; Cansu DU; Nikolopoulos D; Crisafulli F; Antunes AM; Adamichou C; Reid S; Stagnaro C; Andreoli L; Tincani A; Moraes-Fontes MF; Mosca M; Leonard D; Jönsen A; Bengtsson A; Svenungsson E; Gunnarsson I; Dahlqvist SR; Sjöwall C; Bertsias G; Fanouriakis A; Rönnblom L
    Semin Arthritis Rheum; 2020 Dec; 50(6):1387-1393. PubMed ID: 32229040
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disease-modifying effect and long-term safety of belimumab in patients with systemic lupus erythematosus: A single-center retrospective study.
    Nakai T; Fukui S; Sawada H; Ikada Y; Tamaki H; Kishimoto M; Okada M
    Lupus; 2023 Nov; 32(13):1518-1527. PubMed ID: 37858981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort.
    Andrade RM; Alarcón GS; Fernández M; Apte M; Vilá LM; Reveille JD;
    Arthritis Rheum; 2007 Feb; 56(2):622-30. PubMed ID: 17265497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does expert opinion match the definition of lupus low disease activity state? Prospective analysis of 500 patients from a Spanish multicentre cohort.
    Altabás-González I; Rúa-Figueroa I; Rubiño F; Mouriño Rodríguez C; Hernández-Rodríguez I; Menor Almagro R; Uriarte Isacelaya E; Tomero Muriel E; Salman-Monte TC; Carrión-Barberà I; Galindo M; Rodríguez Almaraz EM; Jiménez N; Inês L; Pego-Reigosa JM
    Rheumatology (Oxford); 2023 Mar; 62(3):1162-1169. PubMed ID: 35961050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.